4J THERAPEUTICS INC
4J THERAPEUTICS INC is a federal contractor, registered under UEI SZCGV7LQJKR4 and CAGE code 9DFF0. It has been awarded $37,589,800 across 1 federal contract. Primary work spans Research and Development in Biotechnology (except Nanobiotechnology). Top awarding agencies include Department Of Health And Human Services.
Contact Information
Registration and classification details
Registration
UEI Code
SZCGV7LQJKR4CAGE Code
9DFF0Entity Structure
Corporate Entity (Not Tax Exempt)Established
N/ABusiness Classifications
NAICS Codes
Federal Contracting Overview
Award totals, agency breakdown, NAICS distribution, and geographic footprint.
AI Capability Profile
4J Therapeutics Inc. specializes in the research and development of programmable antiviral technologies, focusing on the design, preclinical validation, and early-stage clinical evaluation of novel therapeutic platforms. Their core expertise lies in nucleic acid-based drug discovery, particularly le...
4J Therapeutics Inc. specializes in the research and development of programmable antiviral technologies, focusing on the design, preclinical validation, and early-stage clinical evaluation of novel therapeutic platforms. Their core expertise lies in nucleic acid-based drug discovery, particularly leveraging locked nucleic acid (LNA) chemistries to engineer targeted antiviral agents with high specificity and potency. The company develops end-to-end preclinical packages, including pharmacokinetic profiling, toxicology studies, and formulation science, to advance candidates into first-in-human Phase 1A trials. Their technical differentiator is the modular design of their platform, enabling rapid adaptation to emerging viral threats while maintaining robust safety and manufacturability profiles. This positions them at the intersection of molecular virology, oligonucleotide therapeutics, and translational medicine. The company has demonstrated direct engagement with the Department of Health and Human Services, where its work supports public health preparedness through the advancement of next-generation antiviral candidates. This relationship reflects a focus on mission-critical biodefense and infectious disease innovation aligned with HHS’s strategic priorities in pandemic response and biomedical R&D. 4J Therapeutics operates primarily within NAICS 541714, which encompasses biotechnology research aimed at therapeutic discovery and development outside of nanobiotechnology. Their vertical specialization is in antiviral platform technologies, with a clear emphasis on RNA-targeting modalities and early-phase clinical translation. This niche places them within the broader landscape of precision antiviral biotech, serving government-funded initiatives focused on novel therapeutic pipelines. As a small business structured as a 2L entity based in Palo Alto, California, 4J Therapeutics leverages its location within a global biotech hub to access scientific talent and research infrastructure. While currently holding no formal government certifications, its focused R&D model and direct engagement with HHS underscore its role as a specialized innovator in the federal biodefense and therapeutic development ecosystem.
Key Performance Metrics
Awards Count
All time
Active
Currently performing
Completed
Past period of performance
Total Awards
All time
Contracts
Prime · all time
Subcontracts
Sub · all time
Grants
Prime · all time
Subgrants
Sub · all time
